

Table S1. siRNAs used in this study

Factor	siRNA sequence ¹
CPSF-160	A: 5'-CCGAGCGUUUCACUUUGACAATT, 5'-UUGUCAAGUGAAACGCUCGGTT B: 5'-CCGCAAUCUUAUGGUGUAUAUTT, 5'-AUUAACACCAUAAGAUUGCGGTT
CPSF-100	5'-CUCGACACAAUACAGAAGAUUTT, 5'-AAUCUUCUGUAUUGUGUCGAGTT
CPSF-73	5'-CCAGCAAACCAGUGAAUUUAUTT, 5'-AUAAAUUCACUGGUUUGCUGGTT
CPSF-30	5'-ACGCCAACAGAUAGCACCAAAGTT, 5'-CUUUGGUGCAUCUGUUGGCGGTT
Fip1	A: 5'-GUGCUGAUCUUUCUGAUUATT, 5'-UAAUCAGAAAGAUAGCACTT B: 5'-CGUCGCCAUGAAAGUGAAGAATT, 5'-UUCUUCACUUUCAUGGCGACGTT
WDR33	5'-CUCCAAAUGAGGUGCUGAAUTT, 5'-AUUCAGCACCUCAUUUGGAGTT
CstF-50	5'-GCUCUACGACGGUUAUUAUTT, 5'-AAUGUAACCGUCGUAGAGCAG
CstF-64	A: 5'-GCUGGCAACAAAUCUGGAAAUTT, 5'-AUUCCAGAUUUGUUGCCAGCTT B: 5'-GCACAGGUAGUGAUGAGAAUUTT, 5'-AAUUCUCAUCACUACCUGUGCTT
CstF-64r	5'-GCACAAGUGGUGAUGAGAATT, 5'-UUCUCAUACCCACUUGUGCCT
CstF-77	5'-CGAGGAUUCAGACGAAGAATT, 5'-AUCUUCGUCUGAAUCCUCGTT
CFI-25	A: 5'-CGUCUCUAUGAGCACAGCUUATT, 5'-UAAGCUGUGCUCAUAGAGACGTT B: 5'-GCACCAUUGUUUGAGCUGUAUTT, 5'-AUACAGCUCAAACAAUGGUGCTT
CFI-68	A: 5'-CCUGUUGUAAACUCCAUGCAAUTT, 5'-AUUGCAUGGAGUUACAACAGGTT B: 5'-CCGUUCAUUCUUUGGGAGUAATT, 5'-UUACUCCCAAAGAAUGAACGGTT
CFI-59	5'-GUCCUCAUCUCCUCUCUUAUTT, 5'-UAAGAGAGGAGAUGAGGACTT
Pcf11 ²	A: 5'-CGACAGCUAUUUCAGUAUCAATT, 5'-UUGAUACUGAAAUAGCUGUCGTT B: 5'-GGGCAAAGAUGAAGAUGUAUTT, 5'-UACAUCUUCAUUCUUUGCCCTT
Clp1	A: 5'-GAGAUGAACGUAUCCGUGATT, 5'-UCACGGAUACGUUCAUCUCTA B: 5'-CGUCCUACUUCAGUGGAGUUATT, 5'-UACUCCACGUAAGUAGGACGTT
Symplekin	5'-UCAGGCACUCUGGACAAAUAUTT, 5'-AUUUUUGUCCAGAGUGCCUGATT
PAP α	5'-UUGCAGGGUAACCGAUGAAAUTT, 5'-AUUUCAUCGGUUAACCCUGCAATT
PAP γ	5'-AUGUGGUUCCUUGGGAUAAUUTT, 5'-AAUUAUCCCAAGGAACCAUAUTT
PABPN1 ²	A: 5'-UAGAGCGACAUCUAGGUUAUUCTT, 5'-GAAUACCAUGAUGUCGCUCUATT B: 5'-ACAGUUUGGUGUCCUCCAGAGAGC, 5'-GCTCTCTGGUUGGUCUCCUUUCTGT
PABPC1 ²	A: 5'-CGUGCUUUGGACACCAUGAAUTT, 5'-AUUCAUGGUGUCCAAAGCACGTT B: 5'-UAAAGCUACAUCAGUGGCUUCGUG, 5'-CUCGUUGCCUCTGTUTGTUGCTTTU
PP1 α	5'-CCAGAUUCGUUUGUACAGAAAUTT, 5'-AUUUCUGUACAAACGAUCUGGTT
PP1 β	5'-GAGGAAACCAUGAGUGUGCUATT, 5'-UAGCACACUCAUGGUUUCUUCTT
RBBP6	A: 5'-GAUUGUCAGGAGGAUUCUAUTT, 5'-AUAGGAUCCUCCUGACAAUUCTT B: 5'-CGAUCACUUUCAAGUCAGUAUTT, 5'-AUACUGACUUGAAAGUGAUCGTT
U2AF65	A: 5'-GCAACUGGAAUGGCAGCAAUUTT, 5'-AAUUGCUGCCAUUCCAGUUGCTT B: 5'-GUGAGUACGUGGACAUAUATT, 5'-UUGAUGUCCACGUACUACTT
SF3b155	A: 5'-GCCUGCCUUAUUGAAUGAAUATT, 5'-UAUUCAUUCAUUAAGGCAGGCTT B: 5'-GUCACUUGGUGUUUACGGATT, 5'-UCCGUAAACACCAAGUGACAT
U1-70K	A: 5'-GCACCAUACAUCGAGAGUUUTT, 5'-AAACUCUCGGAUGUAUGGUGCTT B: 5'-CCCUCACAAUGAUCCCAAUTT, 5'-AUUGGGAUCAUUGUGAGGGTC
RRP44	A: 5'-GCGUUAGAAGGACGGAGAAUUTT, 5'-AAUUCUCCGUCCUUCUAACGCTT B: 5'-GCGGCUAUGAAUGAUGAUATT, 5'-UAUCAUCAUUCUAAGCCGCTT
RRP6	A: 5'-GUUCGGUGACGAGUAUGAUUUTT, 5'-AAAUCAUACUCGUCACCGAACTT B: 5'-GGUCCAGAAAGAACCUAUATT, 5'-UUUAGGUUCUUUCUGGACCTT
siCtrl ³	5'-UUCUCCGAACGUGUCACGUTT, 5'-ACGUGACACGUUCGGAGAATT

¹Some knockdowns include two siRNAs. They are indicated by A and B.

²Only siRNA A was used for 48 hr knockdown samples. Both A and B siRNAs were used for 32 hr knockdown samples.

³siRNA negative control is a random sequence with no detectable homology with any mammalian genes (obtained from GenePharma).